Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07339800
Recruiting Observational

Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value

NCT07339800 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Strasbourg, France
Phase
Observational
Started
2025-09-18
Last updated
2026-01-14

Condition(s) studied

Pulmonary Mucormycosis

Study summary

Invasive pulmonary fungal infections caused by Mucorales are rare but severe and rapidly progressive, affecting immunocompromised patients. The role of chest imaging in their diagnosis is well established in the 2020 EORTC/MSGERC criteria, and its use is almost systematic. However, the progression of lung parenchymal involvement and any potential prognostic radiological patterns in the follow-up of these infections are less well understood. This research aims to identify imaging characteristics predictive of favorable or unfavorable outcomes in infected patients, in order to better tailor follow-up and therapeutic options.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 years or older * Treated at Strasbourg University Hospital between January 1, 2009, and June 3, 2025 * With a diagnosis of probable or proven invasive pulmonary infection with Mucorales according to the 2020 EORTC/MSGERC criteria * Having undergone at least one CT scan including the thoracic region Exclusion Criteria: * No CT scan including the thoracic region * No diagnosis of probable or proven invasive pulmonary infection with Mucorales (EORTC/MSGERC 2020 criteria)

Primary outcome measure(s)

  • Death rate in patients with probable or proven invasive Mucorales infection — Day 15 after infection
    Death rate at day 15 in patients with probable or proven invasive Mucorales infection

Trial sites (1)

FacilityCityRegionStatus
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France Strasbourg France Recruiting

More University Hospital, Strasbourg, France trials in France

The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers Active, not recruiting
Dynamical Electrophysiology and Neuropathology in Lewy's Bodies Disease Recruiting
Impact of Perioperative Organ Resuscitation of Brain-dead Deceased Organ Donor on Kidney Graft Function in the Recipient Recruiting
Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine Recruiting
Study of the Care Pathway of Patients Admitted to the Palliative Care Unit of Strasbourg University Hospital From Their Home in 2025 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07339800 on ClinicalTrials.gov ↗ ← All trials in France